# Hygieia Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hygieia-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.hygieiapharma.com
- Latest round: Series A (Sep 3, 2024)
- Investors on record: 2

## About

Founded in 2021 and based in Shanghai, China, Hygieia Pharmaceuticals is a biopharmaceutical company that focuses on the construction of siRNA delivery technology platform. In Seotember 2024, the firm closed a series A2 funding.

The company's main products include MVIP delivery platform, DDP delivery platform and NSDP delivery platform. DDP is a second-generation siRNAs delivery technology platform developed by Hejia for liver diseases. The company is also developing drugs to treat liver disease, cardiovascular and cerebrovascular and metabolic diseases.

The company’s revenue is generated by providing siRNA delivery technology platform and coupled delivery of siRNA small nucleic acid drugs.

The company will use the funding for the development of multiple Phase I clinical pipelines to provide additional funding for the development of more IND enabling projects and to improve the early research and development of extrahepatic delivery platform technology.

## Funding rounds

- Series A, Sep 3, 2024 — Leading Capital, Huangpu Biomedical Investment

## Investors

- Leading Capital — Series A
- Huangpu Biomedical Investment (https://capitalatlas.ai/funds/huangpu-biomedical-investment) — Series A